Literature DB >> 28381955

Management Of Primary Sclerosing Cholangitis.

Bimaljit S Sandhu1, Velimir A Luketic1.   

Abstract

Management of primary sclerosing cholangitis (PSC) can be divided into endoscopic, medical, and surgical treatments. Whereas endoscopic therapy is primarily used to manage dominant strictures, medical treatment is directed both at modifying course of the disease and at symptomatic relief. Ursodeoxycholic acid is the most promising disease-modifying agent. Corticosteroids and other immunosuppressive agents do not have a proven role. Cholestyramine and rifampicin improve pruritis but response to these agents cannot be reliably predicted. Opioid antagonists are useful in refractory pruritis. All patients with advanced PSC should be offered bone mineral-density measurement and, if needed, treatment for osteoporosis. These approaches are not mutually exclusive and are often used concurrently or in sequence depending on the clinical situation. Liver transplantation is the only therapy that improves survival. In this review, we discuss the various management options for PSC.

Entities:  

Keywords:  Primary sclerosing cholangitis; immunosuppressives; liver transplant; ursodeoxycholic acid

Year:  2006        PMID: 28381955      PMCID: PMC5368615     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN: 1554-7914


  88 in total

1.  A prognostic model for the outcome of liver transplantation in patients with cholestatic liver disease.

Authors:  P Ricci; T M Therneau; M Malinchoc; J T Benson; J L Petz; G B Klintmalm; J S Crippin; R H Wiesner; J L Steers; J Rakela; T E Starzl; E R Dickson
Journal:  Hepatology       Date:  1997-03       Impact factor: 17.425

2.  Inhibition of the MAPK and PI3K pathways enhances UDCA-induced apoptosis in primary rodent hepatocytes.

Authors:  Liang Qiao; Adly Yacoub; Elaine Studer; Seema Gupta; Xin Yan Pei; Steven Grant; Philip B Hylemon; Paul Dent
Journal:  Hepatology       Date:  2002-04       Impact factor: 17.425

3.  Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines.

Authors:  E J Heathcote
Journal:  Hepatology       Date:  2000-04       Impact factor: 17.425

4.  Balloon dilation compared to stenting of dominant strictures in primary sclerosing cholangitis.

Authors:  M Kaya; B T Petersen; P Angulo; T H Baron; J C Andrews; C J Gostout; K D Lindor
Journal:  Am J Gastroenterol       Date:  2001-04       Impact factor: 10.864

5.  A pilot study of pentoxifylline for the treatment of primary sclerosing cholangitis.

Authors:  A E Bharucha; R Jorgensen; S N Lichtman; N F LaRusso; K D Lindor
Journal:  Am J Gastroenterol       Date:  2000-09       Impact factor: 10.864

6.  Tauroursodeoxycholic acid inserts the apical conjugate export pump, Mrp2, into canalicular membranes and stimulates organic anion secretion by protein kinase C-dependent mechanisms in cholestatic rat liver.

Authors:  U Beuers; M Bilzer; A Chittattu; G A Kullak-Ublick; D Keppler; G Paumgartner; F Dombrowski
Journal:  Hepatology       Date:  2001-05       Impact factor: 17.425

7.  Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment.

Authors:  Adolf Stiehl; Gerda Rudolph; Petra Klöters-Plachky; Peter Sauer; Siegfried Walker
Journal:  J Hepatol       Date:  2002-02       Impact factor: 25.083

8.  A double-blind controlled trial of oral-pulse methotrexate therapy in the treatment of primary sclerosing cholangitis.

Authors:  T A Knox; M M Kaplan
Journal:  Gastroenterology       Date:  1994-02       Impact factor: 22.682

9.  Treatment of pruritus of primary biliary cirrhosis with rifampin.

Authors:  A Podesta; P Lopez; R Terg; F Villamil; D Flores; R Mastai; C B Udaondo; J P Companc
Journal:  Dig Dis Sci       Date:  1991-02       Impact factor: 3.199

10.  Induction of hepatic microsomal enzymes after brief administration of rifampicin in man.

Authors:  J P Miguet; P Mavier; C J Soussy; D Dhumeaux
Journal:  Gastroenterology       Date:  1977-05       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.